<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="EN">
    <front>
        <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, USA</publisher-loc>
            </publisher></journal-meta>
        <article-meta><article-id pub-id-type="publisher-id">08-PLCB-RA-0703R2</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1000246</article-id><article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline">
                    <subject>Computational Biology</subject>
                    <subject>Immunology/Antigen Processing and Recognition</subject>
                    <subject>Immunology/Immune Response</subject>
                    <subject>Public Health and Epidemiology/Immunization</subject>
                    <subject>Virology/Vaccines</subject>
                </subj-group>
            </article-categories><title-group><article-title>A Mathematical Framework for the Selection of an Optimal Set of
                    Peptides for Epitope-Based Vaccines</article-title><alt-title alt-title-type="running-head">Selection of Optimal Peptide Sets for
                    Vaccines</alt-title></title-group><contrib-group>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Toussaint</surname>
                        <given-names>Nora C.</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"/>
                    <xref ref-type="corresp" rid="cor1">
                        <sup>*</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Dönnes</surname>
                        <given-names>Pierre</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"/>
                    <xref ref-type="fn" rid="fn1">
                        <sup>¤</sup>
                    </xref>
                </contrib>
                <contrib contrib-type="author" xlink:type="simple">
                    <name name-style="western">
                        <surname>Kohlbacher</surname>
                        <given-names>Oliver</given-names>
                    </name>
                    <xref ref-type="aff" rid="aff1"/>
                </contrib>
            </contrib-group><aff id="aff1">
                <addr-line>Simulation of Biological Systems, Center for Bioinformatics, Eberhard
                    Karls University Tübingen, Tübingen, Germany</addr-line>
            </aff><contrib-group>
                <contrib contrib-type="editor" xlink:type="simple">
                    <name name-style="western">
                        <surname>De Boer</surname>
                        <given-names>Rob J.</given-names>
                    </name>
                    <role>Editor</role>
                    <xref ref-type="aff" rid="edit1"/>
                </contrib>
            </contrib-group><aff id="edit1">Utrecht University, Netherlands</aff><author-notes>
                <corresp id="cor1">* E-mail: <email xlink:type="simple">toussaint@informatik.uni-tuebingen.de</email></corresp>
                <fn fn-type="current-aff" id="fn1">
                    <label>¤</label>
                    <p>Current address: Molecular Toxicology, Safety Assessment, AstraZeneca
                        R&amp;D, Södertälje, Sweden</p>
                </fn>
                <fn fn-type="con">
                    <p>Conceived and designed the experiments: NCT PD OK. Performed the experiments:
                        NCT. Analyzed the data: NCT OK. Wrote the paper: NCT PD OK.</p>
                </fn>
            <fn fn-type="conflict">
                <p>The authors have declared that no competing interests exist.</p>
            </fn></author-notes><pub-date pub-type="collection">
                <month>12</month>
                <year>2008</year>
            </pub-date><pub-date pub-type="epub">
                <day>26</day>
                <month>12</month>
                <year>2008</year>
            </pub-date><volume>4</volume><issue>12</issue><elocation-id>e1000246</elocation-id><history>
                <date date-type="received">
                    <day>19</day>
                    <month>8</month>
                    <year>2008</year>
                </date>
                <date date-type="accepted">
                    <day>6</day>
                    <month>11</month>
                    <year>2008</year>
                </date>
            </history><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2008</copyright-year><copyright-holder>Toussaint et al</copyright-holder><license><license-p>This is an open-access article distributed under
                the terms of the Creative Commons Attribution License, which permits unrestricted
                use, distribution, and reproduction in any medium, provided the original author and
                source are credited.</license-p></license></permissions><abstract>
                <p>Epitope-based vaccines (EVs) have a wide range of applications: from therapeutic
                    to prophylactic approaches, from infectious diseases to cancer. The development
                    of an EV is based on the knowledge of target-specific antigens from which
                    immunogenic peptides, so-called epitopes, are derived. Such epitopes form the
                    key components of the EV. Due to regulatory, economic, and practical concerns
                    the number of epitopes that can be included in an EV is limited. Furthermore, as
                    the major histocompatibility complex (MHC) binding these epitopes is highly
                    polymorphic, every patient possesses a set of MHC class I and class II molecules
                    of differing specificities. A peptide combination effective for one person can
                    thus be completely ineffective for another. This renders the optimal selection
                    of these epitopes an important and interesting optimization problem. In this
                    work we present a mathematical framework based on integer linear programming
                    (ILP) that allows the formulation of various flavors of the vaccine design
                    problem and the efficient identification of optimal sets of epitopes. Out of a
                    user-defined set of predicted or experimentally determined epitopes, the
                    framework selects the set with the maximum likelihood of eliciting a broad and
                    potent immune response. Our ILP approach allows an elegant and flexible
                    formulation of numerous variants of the EV design problem. In order to
                    demonstrate this, we show how common immunological requirements for a good EV
                    (e.g., coverage of epitopes from each antigen, coverage of all MHC alleles in a
                    set, or avoidance of epitopes with high mutation rates) can be translated into
                    constraints or modifications of the objective function within the ILP framework.
                    An implementation of the algorithm outperforms a simple greedy strategy as well
                    as a previously suggested evolutionary algorithm and has runtimes on the order
                    of seconds for typical problem sizes.</p>
            </abstract><abstract abstract-type="summary">
                <title>Author Summary</title>
                <p>Over the last decade the design of tailor-made vaccines for prophylactic
                    applications (e.g., prevention of infection) and therapeutic applications (e.g.,
                    cancer therapy) has attracted significant interest. Epitope-based vaccines are
                    good candidates for such tailor-made approaches. They trigger an immune response
                    by confronting the immune system with immunogenic peptides derived from, e.g.,
                    viral- or cancer-specific proteins. These peptides bind to major
                    histocompatibility complex (MHC) molecules in a specific manner. The resulting
                    complex is crucial for immune system activation. However, there are many allelic
                    variants of MHC molecules, meaning that different patients typically bind
                    different repertoires of peptides. Nevertheless, due to economical and
                    regulatory issues one cannot simply add all immunogenic peptides to such a
                    peptide mix. Hence, it is crucial to identify the optimal set of peptides for a
                    vaccine, given constraints such as MHC allele frequencies in the target
                    population, peptide mutation rates, and maximum number of selected peptides. In
                    this work we formalize this problem, and variants thereof, in a mathematical
                    framework. The resulting optimization problem can be solved efficiently and
                    yields a provably optimal peptide combination. We can show that the method
                    performs better than existing solutions. Furthermore, the framework is highly
                    flexible and can easily handle additional criteria.</p>
            </abstract><funding-group><funding-statement>This work was funded in part by the Deutsche Forschungsgemeinschaft (Grant
                    SFB685/B1).</funding-statement></funding-group><counts>
                <page-count count="10"/>
            </counts></article-meta>
    </front>
    <body>
        <sec id="s1">
            <title>Introduction</title>
            <p>The development of vaccines and their subsequent large-scale prophylactic use was
                undoubtedly one of the most important developments in medicine. Vaccines make use of
                the adaptive part of the human immune system to protect from future infections
                (e.g., prophylactic vaccines used against viruses) as well as to fight chronic
                diseases and cancer.</p>
            <p>Cellular adaptive immunity is, at its core, triggered by the recognition of
                immunogenic peptides bound to MHC class I (MHC I) and II molecules by T-cell
                receptors located on the surface of T cells. These peptides are derived from
                antigens, i.e., proteins that can cause an immune response, as a result of rather
                complex antigen processing pathways <italic>in vivo</italic>. Peptides capable of
                causing such an immune response are called epitopes and represent the smallest
                subunits that may be used therapeutically.</p>
            <p>There are numerous options for constructing a vaccine once a set of potential
                antigens is known. The antigens or parts thereof can be used as intact proteins
                    <xref ref-type="bibr" rid="pcbi.1000246-Moutschen1">[1]</xref>,<xref ref-type="bibr" rid="pcbi.1000246-Goepfert1">[2]</xref>, they can be administered as RNA or DNA coding for
                the antigen <xref ref-type="bibr" rid="pcbi.1000246-Nemunaitis1">[3]</xref>,<xref ref-type="bibr" rid="pcbi.1000246-ManciniBourgine1">[4]</xref>, or the
                epitopes contained in the antigens may be used for vaccines. As discussed in detail
                in <xref ref-type="bibr" rid="pcbi.1000246-Purcell1">[5]</xref>
                the use of epitope-based vaccines (EVs) brings about manifold advantages, e.g.,
                safety, ease of production, analytical control, and distribution. Skilled selection
                of epitopes can precisely direct the evoked immune response at conserved and highly
                immunogenic regions of several antigens. Due to these advantages and the
                applicability in personalized vaccination, EVs have recently been getting more and
                more attention. The recent review of EVs by Purcell <italic>et al.</italic>
                <xref ref-type="bibr" rid="pcbi.1000246-Purcell1">[5]</xref> gives
                a good overview of the state of the art as well as its achievements. We will thus
                only point out some recent studies.</p>
            <p>EVs have proven successful in preclinical trials in mice <xref ref-type="bibr" rid="pcbi.1000246-Depil1">[6]</xref>, on which many of the
                preliminary studies have been conducted. A large number of clinical studies, both
                from academia and industry, have also been successful and have entered and/or
                completed clinical phase I and II trials <xref ref-type="bibr" rid="pcbi.1000246-ChianeseBullock1">[7]</xref>–<xref ref-type="bibr" rid="pcbi.1000246-Slingluff2">[11]</xref>.
                Several commercial products have now entered clinical phase III trials. The
                indications for the vaccines in trial are mostly various cancers (e.g., leukemia,
                colorectal cancer, gastric cancer, lung cancer) and infectious diseases
                (predominantly HIV and hepatitis C virus).</p>
            <p>The design of an EV entails one critical step, the selection of the epitopes. From
                the set of antigens, one can experimentally determine or computationally predict
                epitopes for a variety of MHC alleles. The crucial task is to select the set of
                epitopes which yields the best immune response in a given population while at the
                same time keeping the number of epitopes low. This step is of course critical to the
                success of the vaccine. The selection is usually made on a case-by-case basis
                considering key properties for each epitope: overall immunogenicity, mutation
                tolerance, population coverage, antigen coverage, and antigen processing.</p>
            <p>The selection methods used by the pharmaceutical industry are manifold. In 2004,
                Singh-Jasuja <italic>et al.</italic> presented the Tübingen approach <xref ref-type="bibr" rid="pcbi.1000246-SinghJasuja1">[12]</xref> to
                acquire an experimentally validated initial list of epitopes from tumor associated
                antigens. In this work, the incorporation of computational methods for prediction of
                MHC-peptide binding in the process is proposed. Since they help to reduce the number
                of experiments to be performed, such prediction methods have become standard tools
                in immunology. Commonly used methods are SYFPEITHI <xref ref-type="bibr" rid="pcbi.1000246-Rammensee1">[13]</xref>, HLA_BIND/Bimas
                    <xref ref-type="bibr" rid="pcbi.1000246-Parker1">[14]</xref>,
                SVMHC <xref ref-type="bibr" rid="pcbi.1000246-Dnnes1">[15]</xref>,
                NetMHC <xref ref-type="bibr" rid="pcbi.1000246-Buus1">[16]</xref>–<xref ref-type="bibr" rid="pcbi.1000246-Nielsen2">[18]</xref>, EpiMatrix <xref ref-type="bibr" rid="pcbi.1000246-Schafer1">[19]</xref>, and
                the methods <xref ref-type="bibr" rid="pcbi.1000246-Bui1">[20]</xref>–<xref ref-type="bibr" rid="pcbi.1000246-Sturniolo1">[23]</xref> provided by the
                Immune Epitope Database <xref ref-type="bibr" rid="pcbi.1000246-Peters2">[24]</xref>.</p>
            <p>Given the set of candidate peptides, computational methods can be used to determine
                the relevant attributes of each candidate. However, the final choice of the set of
                epitopes to be used in the vaccine is typically performed manually. Several groups
                have addressed this problem computationally. In 2005, DeGroot <italic>et al.</italic>
                <xref ref-type="bibr" rid="pcbi.1000246-Groot1">[25]</xref>
                published an approach to creating highly immunogenic and conserved epitopes to be
                used in EVs. The authors use EpiMatrix <xref ref-type="bibr" rid="pcbi.1000246-Schafer1">[19]</xref> to estimate the MHC
                class II binding affinity of highly conserved 9mers from HIV-1 proteins. Peptides
                with high binding affinities are then used to construct extended peptides containing
                multiple overlapping 9mers. <italic>In vitro</italic> evaluation of the
                immunogenicity of a selected set of these extended peptides yielded positive
                results.</p>
            <p>Recently, Vider-Shalit <italic>et al.</italic>
                <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref>
                proposed using a genetic algorithm to design an ordered sequence of epitopes to be
                used in an EV. Information on peptide conservation and similarity to self-peptides
                is used to pre-filter the set of candidates, while information on MHC allele
                frequencies is used to select alleles of interest. The scoring function used for the
                heuristic takes into account the number of covered MHC alleles, the number of
                covered antigens, the number of covered MHC/antigen combinations, and the
                probability of each epitope to be properly cleaved in the sequence.</p>
            <p>Two related approaches were published by Fischer <italic>et al.</italic>
                <xref ref-type="bibr" rid="pcbi.1000246-Fischer1">[27]</xref> and
                Nickle <italic>et al.</italic>
                <xref ref-type="bibr" rid="pcbi.1000246-Nickle1">[28]</xref>. Both
                groups focus on designing vaccine antigens capable of protecting against diverse
                HIV-1 strains. In order to do so, they use computational methods to compress the
                variation found in naturally occurring antigens into a small number of composite
                antigens.</p>
            <p>Common to the computational approaches above (and of course manual selection) is the
                fact that the solutions are not necessarily optimal. None of the approaches can
                guarantee that there is not a better vaccine possible from the given set of
                epitopes. In this work we propose an integer linear programming approach to finding
                a provably optimal set of epitopes for an EV. Given a set of candidate peptides, a
                set of MHC alleles of interest, information on the peptides' respective
                immunogenicities along with other information to be incorporated into the selection
                process, our framework is capable of finding the set of epitopes yielding the
                highest possible overall immunogenicity (<xref ref-type="fig" rid="pcbi-1000246-g001">Figure 1</xref>). The resulting integer linear program
                can be solved very efficiently for all practical problem sizes (runtimes of a few
                seconds) and can thus be readily applied. With respect to various quality criteria
                (population coverage, antigen coverage, overall immunogenicity), the approach
                outperforms a simple greedy heuristic (‘pick the <italic>k</italic> best
                epitopes’) and also a genetic algorithm. The elegant mathematical
                formulation turns out to be flexible enough to also account for variants of the
                problem, e.g., the application to personalized vaccines. To our knowledge, this is
                the first epitope selection framework that finds the optimal solution.</p>
            <fig id="pcbi-1000246-g001" position="float">
                <object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.g001</object-id>
                <label>Figure 1</label>
                <caption>
                    <title>Basic idea behind this work.</title>
                    <p>Starting from target antigens, a list of properties of interest, and a target
                        population the information necessary to determine an optimal set of epitopes
                        is derived (gray boxes). Given this information, a mathematical framework
                        can conveniently be used to find the set of epitopes that is optimal with
                        respect to the target population and the properties of interest.</p>
                </caption>
                <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.g001" xlink:type="simple"/>
            </fig>
        </sec>
        <sec id="s2">
            <title>Materials and Methods</title>
            <sec id="s2a">
                <title>Approach</title>
                <p>In order to find an optimal set of epitopes, we first have to define what
                    characterizes a <italic>good</italic> vaccine or, correspondingly, a
                        <italic>good</italic> set of epitopes. This issue is highly controversial in
                    the literature and only large-scale data from vaccination trials will provide
                    sufficient data to validate the different approaches retrospectively. With this
                    in mind, we do not suggest one optimal epitope selection strategy, but instead
                    suggest a mathematical framework that allows working with various definitions of
                    the term ‘good vaccine’. For a chosen definition, however,
                    the algorithms will yield a combination of epitopes that is provably optimal.</p>
                <p>In the following, we will introduce a ‘reasonable’ definition
                    of a good vaccine. This will allow us to present the mathematical formulation
                    and to illustrate how immunological requirements can be translated into
                    mathematical constraints. For specific applications, the requirements and
                    constraints may of course deviate from those given. For example, sequence
                    variation in an antigen would be much more important for an HIV vaccine than for
                    a cancer vaccine. The framework is flexible enough to allow for such different
                    requirements, as we will illustrate towards the end of the work.</p>
                <p>A good vaccine displays a high overall immunogenicity, which means it is capable
                    of inducing potent immunity in a large fraction of the target population. This
                    basic definition forms the basis of our mathematical formulation which aims at
                    maximizing overall immunogenicity of the selected epitopes. We extend this
                    definition by additionally requiring high mutation tolerance as well as a
                    certain degree of allele and antigen coverage. Furthermore, the selected
                    epitopes should display a high probability of passing through the antigen
                    processing pathway. We thus obtain a brief list of basic requirements:</p>
                <sec id="s2a1">
                    <title>Mutation tolerance</title>
                    <p>Mutations within the targeted antigen regions can lead to an escape from
                        immune response. High genetic variability as observed in, e.g., HIV, the
                        hepatitis C virus, and influenza can thus affect protection by a vaccine.
                        Selection of highly conserved non-overlapping epitopes reduces the chance of
                        immune escape.</p>
                </sec>
                <sec id="s2a2">
                    <title>Allele coverage</title>
                    <p>Because the MHC is polygenic, every individual possesses a set of MHC loci.
                        Due to the high polymorphicity of these loci, the pool of MHC molecules
                        varies from individual to individual. The allelic form of an MHC molecule
                        determines the spectrum of peptides the molecule can bind. Within a
                        population alleles occur with different frequencies. Hence, requiring a
                        certain number of alleles to be covered is equivalent to requiring a certain
                        degree of population coverage. An MHC allele is said to be covered by a set
                        of epitopes if at least one of the epitopes is capable of inducing an immune
                        response when bound to the corresponding MHC molecule.</p>
                </sec>
                <sec id="s2a3">
                    <title>Antigen coverage</title>
                    <p>The expression frequencies of viral proteins differ. Selecting epitopes from
                        a wide variety of antigens increases the chance of detecting a virus at any
                        developmental stage.</p>
                </sec>
                <sec id="s2a4">
                    <title>Antigen processing</title>
                    <p>Before a peptide is presented by an MHC molecule on the cell surface it
                        passes through an antigen processing pathway, which includes proteasomal
                        cleavage and TAP transport. Knowledge of these steps' specificities
                        allows exclusion of peptides which are unlikely to ever be presented to a T
                        cell.</p>
                    <p>From all possible epitope combinations, the ones with a maximum overall
                        immunogenicity will be called ‘optimal’ (there may be
                        more than one optimal epitope combination). Hence, the search for an optimal
                        epitope set for an EV can be interpreted as an optimization problem: out of
                        a given set of epitopes, choose a subset which, out of all subsets meeting
                        the above-named requirements, displays maximum overall immunogenicity. Since
                        health agencies such as the FDA require proof of the effectiveness and
                        safety of every individual component of a vaccine, the size of such a subset
                        is usually kept rather small (up to a dozen peptides).</p>
                </sec>
            </sec>
            <sec id="s2b">
                <title>Mathematical Abstraction</title>
                <p>Given a set of epitopes and a set of MHC alleles we assume a linear relationship
                    to exist between (a) the immune response induced by all epitopes with respect to
                    all alleles and (b) the immune responses induced by every single one of the
                    epitopes with respect to each of the alleles. Thus, the overall immunogenicity
                    of a set of epitopes depends on the immunogenicity of its components with
                    respect to the different MHC alleles. Furthermore, the contribution of an allele
                    directly depends on its probability of occurring within the target population.
                    (In this context <italic>probability</italic> is commonly referred to as
                        <italic>frequency</italic>. We use <italic>probability</italic> since it is
                    the mathematically correct term.) More common alleles are weighted more than
                    uncommon ones. Thus, overall immunogenicity <italic>I</italic> can be derived
                    mathematically as a weighted sum over immunogenicities of epitopes
                    <italic>E</italic> with respect to the given MHC alleles <italic>A</italic>:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e001" xlink:type="simple"/></disp-formula>where <italic>p<sub>a</sub></italic> corresponds to the
                    probability of allele <italic>a</italic> in the target population and
                            <italic>i<sub>e</sub></italic><sub>,<italic>a</italic></sub> to a
                    measure of the immunogenicity of epitope <italic>e</italic> when bound to allele
                        <italic>a</italic> (either experimentally determined or predicted).</p>
            </sec>
            <sec id="s2c">
                <title>Integer Linear Programming</title>
                <p>Our goal is to maximize overall immunogenicity while constraining the possible
                    solutions to sets of peptides which satisfy the above mentioned requirements for
                    a good vaccine. This problem can be conveniently formulated as an integer linear
                    program (ILP). Linear programming deals with the optimization of linear
                    objective functions subject to linear constraints <xref ref-type="bibr" rid="pcbi.1000246-Schrijver1">[29]</xref>. An ILP is a
                    linear program with integral unknowns. While linear programs without integral
                    unknowns can be solved efficiently, ILPs are NP-complete. Nevertheless, there
                    are tools available that find optimal solutions quite efficiently.</p>
                <p>We restate the problem of choosing the optimal set of epitopes as an ILP. Solving
                    the ILP will render an optimal solution according to our definition of an
                    optimal epitope set. (Adapting the ILP to a different definition is
                    straightforward.) For the sake of clarity, we start out with the very basic
                    definition of an optimal epitope set. In the next step the resulting ILP will be
                    extended to represent the more refined definition.</p>
                <p>The set of candidate epitopes is <italic>E</italic>. Each epitope
                        <italic>e</italic>∈<italic>E</italic> is associated with a binary
                    decision variable x<sub>e</sub>, where
                    <italic>x<sub>e</sub></italic> = 1 if the
                    respective epitope belongs to the optimal set and
                    <italic>x<sub>e</sub></italic> = 0 otherwise.
                    The ILP corresponding to the basic definition of an optimal epitope set is shown
                    in <xref ref-type="table" rid="pcbi-1000246-t001">Table 1</xref>. This ILP
                    maximizes overall immunogenicity: epitope immunogenicity with respect to a
                    specific MHC allele is weighted by the allele's probability. The only
                    constraint is the number of epitopes to select.</p>
                <table-wrap id="pcbi-1000246-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.t001</object-id><label>Table 1</label><caption>
                        <title>ILP corresponding to the basic definition of an optimal epitope
                        set.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000246-t001-1" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.t001" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <tbody>
                            <tr>
                                <td align="left" colspan="2" rowspan="1">
                                    <bold>Definitions</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>A</italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Set of observed MHC alleles</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>E</italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Set of candidate epitopes</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="2" rowspan="1">
                                    <bold>Parameters</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>i<sub>e</sub></italic>
                                    <sub>,<italic>a</italic></sub>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Immunogenicity of epitope <italic>e</italic> with
                                    respect to allele <italic>a</italic></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>k</italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Number of epitopes to select</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>p<sub>a</sub></italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Probability of MHC allele <italic>a</italic>
                                    occurring in the target population</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="2" rowspan="1">
                                    <bold>Variables</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">x<sub>e</sub> = 1</td>
                                <td align="left" colspan="1" rowspan="1">If epitope <italic>e</italic> belongs to the
                                    optimal set, otherwise
                                    x<sub>e</sub> = 0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="2" rowspan="1">
                                    <bold>Integer Linear Program</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>Maximize</italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Maximize …</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∑<italic>
                                        <sub>e</sub>
                                    </italic><sub>∈<italic>E</italic></sub>x<sub>e</sub>∑<italic>
                                        <sub>a</sub>
                                    </italic><sub>∈<italic>A</italic></sub><italic>p<sub>a</sub>
                                            i<sub>e</sub></italic><sub>,<italic>a</italic></sub></td>
                                <td align="left" colspan="1" rowspan="1">… Overall immunogenicity</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="2" rowspan="1">
                                    <italic>subject to</italic>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∑<italic>
                                        <sub>e</sub>
                                    </italic><sub>∈<italic>E</italic></sub>x<sub>e</sub> = <italic>k</italic></td>
                                <td align="left" colspan="1" rowspan="1">… And select exactly <italic>k</italic>
                                    peptides.</td>
                            </tr>
                        </tbody>
                    </table></alternatives></table-wrap>
                <p>We will now extend this basic ILP to represent a more refined definition of a
                    good epitope set. In order to implement the additional requirements we introduce
                    another set of binary decision variables: each MHC allele <italic>a</italic> is
                    associated with a variable y<sub>a</sub>. If allele <italic>a</italic> is
                    covered, meaning that an epitope which is sufficiently immunogenic with respect
                    to allele <italic>a</italic> belongs to the optimal set,
                    y<sub>a</sub> = 1, otherwise
                    y<sub>a</sub> = 0. The extended ILP is shown in
                        <xref ref-type="table" rid="pcbi-1000246-t002">Table 2</xref>. It accounts
                    for mutation tolerance by selecting only non-overlapping conserved epitopes, and
                    for allele and antigen coverage. Additional constraints prevent the selection of
                    peptides which are unlikely to result from antigen processing.</p>
                <table-wrap id="pcbi-1000246-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.t002</object-id><label>Table 2</label><caption>
                        <title>ILP corresponding to the extended definition of an optimal epitope
                            set.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000246-t002-2" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.t002" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <tbody>
                            <tr>
                                <td align="left" colspan="3" rowspan="1">
                                    <bold>Definitions</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>A</italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Set of observed MHC alleles</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>E<sub>i</sub></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Set of epitopes from the
                                    <italic>i</italic>-th antigen</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>E</italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Set of all candidate epitopes
                                        (<italic>E</italic> = <italic>E</italic><sub>1</sub>
                                    ∪…∪
                                <italic>E<sub>n</sub></italic>)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>I<sub>a</sub></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Set of epitopes which, when bound to an
                                    MHC allele <italic>a</italic>, display an immunogenicity greater
                                    than or equal to a given threshold
                                    <italic>τ<sup>I</sup></italic></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>I</italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Set of all sufficiently immunogenic
                                    epitopes (<italic>I</italic> = ∪<italic>
                                        <sub>a</sub>
                                    </italic><sub>∈<italic>A</italic></sub><italic>I<sub>a</sub></italic>)</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>O</italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Set of overlapping pairs of
                                epitopes</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" rowspan="1">
                                    <bold>Parameters</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>c<sub>e</sub></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Conservation of epitope
                                    <italic>e</italic></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>i<sub>e</sub></italic>
                                    <sub>,<italic>a</italic></sub>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Immunogenicity of epitope
                                    <italic>e</italic> with respect to allele
                                <italic>a</italic></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>k</italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Number of epitopes to select</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>p<sub>a</sub></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Probability of MHC allele
                                    <italic>a</italic> occurring in the target population</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e002" xlink:type="simple"/></inline-formula>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Probability that epitope
                                    <italic>e</italic> will be produced during antigen
                                processing</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>τ<sup>A</sup></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Minimum number of epitopes from each
                                    antigen to be included</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>τ<sup>AP</sup></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Antigen processing threshold</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>τ<sup>C</sup></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Conservation threshold</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>τ<sup>MHC</sup></italic>
                                </td>
                                <td align="left" colspan="2" rowspan="1">Minimum number of MHC alleles to be
                                    covered</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" rowspan="1">
                                    <bold>Variables</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">x<sub>e</sub> = 1</td>
                                <td align="left" colspan="2" rowspan="1">If epitope <italic>e</italic> belongs
                                    to the optimal set, otherwise
                                    x<sub>e</sub> = 0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">y<sub>a</sub> = 1</td>
                                <td align="left" colspan="2" rowspan="1">If allele <italic>a</italic> is covered
                                    by the optimal set, otherwise
                                    y<sub>a</sub> = 0</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="3" rowspan="1">
                                    <bold>Integer Linear Program</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>Maximize</italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Maximize …</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">∑<italic>
                                        <sub>e</sub>
                                    </italic><sub>∈<italic>E</italic></sub>x<sub>e</sub>∑<italic>
                                        <sub>a</sub>
                                    </italic><sub>∈<italic>A</italic></sub><italic>p<sub>a</sub>
                                            i<sub>e</sub></italic><sub>,<italic>a</italic></sub></td>
                                <td align="left" colspan="1" rowspan="1">… Overall immunogenicity.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="2" rowspan="1">
                                    <italic>subject to</italic>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">∑<italic>
                                        <sub>e</sub>
                                    </italic><sub>∈<italic>E</italic></sub>x<sub>e</sub> = <italic>k</italic></td>
                                <td align="left" colspan="1" rowspan="1">Selects exactly <italic>k</italic> epitopes.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∀<italic>e</italic>∈<italic>E</italic>:</td>
                                <td align="left" colspan="1" rowspan="1">(1−<italic>c<sub>e</sub></italic>)x<sub>e</sub>≤(1−<italic>τ<sup>C</sup></italic>)</td>
                                <td align="left" colspan="1" rowspan="1">Ensures certain degree of epitope
                                conservation.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∀(<italic>p</italic>,
                                        <italic>r</italic>)∈<italic>O</italic>:</td>
                                <td align="left" colspan="1" rowspan="1">x<sub>p</sub>+x<sub>r</sub>≤1</td>
                                <td align="left" colspan="1" rowspan="1">Guarantees that selected epitopes do not
                                overlap.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∀<italic>a</italic>∈<italic>A</italic>:</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e003" xlink:type="simple"/></inline-formula>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Guarantees that
                                    y<sub>a</sub> = 1 only if
                                    allele <italic>a</italic> is covered.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">∑<italic>
                                        <sub>a</sub>
                                    </italic><sub>∈<italic>A</italic></sub>y<sub>a</sub>≥<italic>τ<sup>MHC</sup></italic></td>
                                <td align="left" colspan="1" rowspan="1">Enforces required allele coverage.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∀<italic>i</italic>∈{1,…,<italic>n</italic>}:</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e004" xlink:type="simple"/></inline-formula>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Enforces required antigen coverage.</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">∀<italic>e</italic>∈<italic>E</italic>:</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e005" xlink:type="simple"/></inline-formula>
                                </td>
                                <td align="left" colspan="1" rowspan="1">Selects only epitopes which have a chance of at
                                    least <italic>τ<sup>AP</sup></italic> to result from
                                    antigen processing.</td>
                            </tr>
                        </tbody>
                    </table></alternatives></table-wrap>
                <p>It might be desirable to obtain several optimal or nearly optimal epitope sets.
                    As proposed in <xref ref-type="bibr" rid="pcbi.1000246-Kingsford1">[30]</xref>, this can be achieved by adding the
                    constraints given in eq. (1), where <italic>S<sub>j</sub></italic> represents
                    the optimal set of epitopes found in iteration <italic>j</italic> and
                    <italic>s</italic> represents the number of solutions to be obtained. The ILP
                    has to be solved iteratively <italic>s</italic> times. After each iteration, the
                    ILP for the next iteration <italic>j</italic>+1 is created by adding
                    the corresponding constraint to the ILP of iteration <italic>j</italic>.<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e006" xlink:type="simple"/><label>(1)</label></disp-formula></p>
                <p>Every resulting epitope set differs from all other solutions in at least
                        <italic>q</italic> peptides,
                    1≤<italic>q</italic>≤<italic>k</italic>.</p>
            </sec>
            <sec id="s2d">
                <title>Nonlinear Requirements</title>
                <p>In order to incorporate a requirement into the ILP framework it must be
                    formulated as a linear constraint. There are, however, reasonable requirements
                    which are non-linear. These cannot be incorporated directly. It is possible
                    though to search a sufficiently large set of optimal and suboptimal solutions
                    for the best set of epitopes that yields the required
                    properties—provided that the requirements are feasible. Two examples
                    of reasonable non-linear requirements will be discussed below.</p>
                <sec id="s2d1">
                    <title>Example 1: Population coverage</title>
                    <p>A major interest in vaccine design is population coverage: For what fraction
                        of a target population will the resulting EV be effective? In theory this
                        corresponds to the probability of an individual in the population carrying
                        at least one MHC allele covered by the epitopes in the EV. Given a set of
                        MHC alleles <italic>A</italic> as before and their distribution within a
                        population, the population coverage of a particular set of epitopes can be
                        computed. For this computation the polygenicity of the MHC has to be taken
                        into account. It is
                            <italic>A</italic> = <italic>A</italic><sub>1</sub>
                        ∪…∪ <italic>A<sub>m</sub></italic> with
                                <italic>A<sub>i</sub></italic> being the alleles at locus
                        <italic>i</italic>. Let <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e007" xlink:type="simple"/></inline-formula> be the probability of an allele <italic>a</italic>
                        occurring at the corresponding MHC locus. Then the probability of an
                        individual in the population carrying an allele from the set
                            <italic>A<sub>i</sub></italic> at locus <italic>i</italic> corresponds to<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e008" xlink:type="simple"/></disp-formula>Let y<sub>a</sub> be as described above. It follows that the
                        probability of an individual carrying at least one MHC allele covered by the
                        epitopes in <italic>E</italic>, and thus the population coverage of
                            <italic>E</italic>, is<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e009" xlink:type="simple"/></disp-formula></p>
                </sec>
                <sec id="s2d2">
                    <title>Example 2: Average number of epitopes per individual</title>
                    <p>Population coverage of an epitope set states what fraction of a population
                        carries an MHC allele associated with one of the epitopes. It does not give
                        any information on the number of active epitopes per individual. The number
                        of epitopes within a set which are active for a specific individual depends
                        on the individual's MHC genotype. Given the haploidic probabilities
                        of MHC alleles within a population the probability of MHC genotypes can be
                        calculated. Alleles not included in the set <italic>A</italic> are accounted
                        for by adding a representative allele <italic>X</italic> to each locus. The
                        frequency of the representative at locus <italic>i</italic> results from <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e010" xlink:type="simple"/></inline-formula>.</p>
                    <p>Let <italic>G</italic> be the set of genotypes within the population of
                        interest and <italic>p<sub>g</sub></italic> the probability of genotype
                            <italic>g</italic>. Furthermore, let <italic>b<sub>g</sub></italic> be
                        the number of epitopes in an epitope set <italic>E</italic> which are
                        immunogenic with respect to an MHC allele in <italic>g</italic>. The average
                        number of active epitopes per individual results from<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e011" xlink:type="simple"/></disp-formula></p>
                </sec>
            </sec>
            <sec id="s2e">
                <title>Evaluation</title>
                <p>Vider-Shalit <italic>et al.</italic>
                    <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref> applied their evolutionary-algorithm-based
                    vaccine design method to hepatitis C virus (HCV). We used our framework on
                    similar data and compared the results of both approaches.</p>
                <sec id="s2e1">
                    <title>Data</title>
                    <p>HCV protein sequences (amino acid frame 1) for ten different proteins (C, E1,
                        E2, p7, NS2, NS3, NS4A, NS4B, NS5A, NS5B) and four different subtypes (1a,
                        1b, 2a, 3a) were retrieved from the Los Alamos hepatitis C sequence database
                            <xref ref-type="bibr" rid="pcbi.1000246-Kuiken1">[31]</xref>. For each protein of each subtype a multiple
                        sequence alignment (MSA) was created using MUSCLE <xref ref-type="bibr" rid="pcbi.1000246-Edgar1">[32]</xref>, resulting in 40
                        MSAs. From each MSA a consensus sequence was created. All 9mers from these
                        consensus sequences were regarded as potential epitopes. <italic>In
                        silico</italic> predicted MHC binding affinities using BIMAS matrices <xref ref-type="bibr" rid="pcbi.1000246-Parker1">[14]</xref>
                        are utilized as a measure of immunogenicity. MHC alleles, their probability
                        of occurring in the human population, and binding affinity score thresholds
                        were directly taken from Vider-Shalit <italic>et al.</italic> To allow a
                        comparison of our results with those of Vider-Shalit <italic>et
                        al.</italic>, we adopt their simplistic definition of peptide conservation
                        (A peptide is considered to be at least <italic>x</italic>%
                        conserved if all of its amino acids display a conservation of at least
                            <italic>x</italic>%.) and disregard all insufficiently
                        conserved (&lt;90%) peptides. To score the probability of a
                        peptide being a result of antigen processing, we used the proteasomal
                        cleavage matrix from the supplementary material of <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref>. As noted
                        in several places, the influence of TAP transport is often rather limited
                            <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref>,<xref ref-type="bibr" rid="pcbi.1000246-Dnnes2">[33]</xref>. Consideration
                        of TAP transport is thus omitted for this example.</p>
                    <p>It has to be noted that the accuracies of the prediction methods cause some
                        limitations. MHC-peptide binding can be predicted with relatively high
                        accuracy for many alleles, whereas proteasomal cleavage prediction leaves
                        more room for improvement.</p>
                </sec>
                <sec id="s2e2">
                    <title>Incorporating the scoring function</title>
                    <p>The scoring function <italic>S</italic> of Vider-Shalit <italic>et
                        al.</italic> takes into account the number of covered MHC alleles, the
                        number of covered antigens, the number of covered MHC/antigen combinations,
                        and a score for the probability of each epitope in the ordered sequence
                        being properly cleaved:<disp-formula><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e012" xlink:type="simple"/></disp-formula>Here, <italic>s</italic> represents the ordered sequence of
                        epitopes to be scored. In order to show the flexibility of our approach we
                        incorporate aspects of this function in our ILP. Since the aim of our
                        framework is to select a set of epitopes and not to create an epitope
                        sequence, we omit the factor <italic>p</italic>(<italic>cleave</italic>).</p>
                    <p>Binary variables have to be introduced in order to count the number of
                        covered antigens and the number of covered MHC/antigen combinations:
                        z<sub>i</sub> = 1 if an epitope from the
                            <italic>i</italic>-th antigen belongs to the optimal set and
                        z<sub>i</sub> = 0 otherwise.
                        w<sub>a,i</sub> = 1 if an epitope from the
                            <italic>i</italic>-th antigen, which is sufficiently immunogenic with
                        respect to MHC allele <italic>a</italic>, belongs to the optimal set and
                            w<sub>a,i</sub> = 0 otherwise. Since
                        immunogenicity scores tend to be higher than the weighted sums of the
                        coverage scores and would therefore outweigh them, we scale the
                        immunogenicity by a (purely empirical) factor of 0.1. The resulting ILP
                        still aims at high overall immunogenicity while at the same time extending
                        the coverage of antigens, MHC alleles, and MHC/antigen combinations. The ILP
                        is shown in <xref ref-type="table" rid="pcbi-1000246-t003">Table 3</xref>.</p>
                    <table-wrap id="pcbi-1000246-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.t003</object-id><label>Table 3</label><caption>
                            <title>ILP corresponding to the combined optimization problem.</title>
                        </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000246-t003-3" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.t003" xlink:type="simple"/><table>
                            <colgroup span="1">
                                <col align="left" span="1"/>
                                <col align="center" span="1"/>
                                <col align="center" span="1"/>
                            </colgroup>
                            <tbody>
                                <tr>
                                    <td align="left" colspan="3" rowspan="1">
                                        <bold>Definitions</bold>
                                    </td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>A</italic>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Set of observed MHC alleles</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>E<sub>i</sub></italic>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Set of epitopes from the
                                        <italic>i</italic>-th antigen</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>E</italic>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Set of all candidate epitopes
                                            (<italic>E</italic> = <italic>E</italic><sub>1</sub>
                                        ∪…∪
                                    <italic>E<sub>n</sub></italic>)</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>I<sub>a</sub></italic>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Set of epitopes which, when bound
                                        to an MHC allele <italic>a</italic>, display an
                                        immunogenicity greater than or equal to a given threshold
                                                <italic>τ<sup>I</sup></italic></td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>I</italic>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Set of all sufficiently immunogenic
                                        epitopes (<italic>I</italic> = ∪<italic>
                                            <sub>a</sub>
                                        </italic><sub>∈<italic>A</italic></sub><italic>I<sub>a</sub></italic>)</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="3" rowspan="1">
                                        <bold>Parameters</bold>
                                    </td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>i<sub>e</sub></italic>
                                        <sub>,<italic>a</italic></sub>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Immunogenicity of epitope
                                        <italic>e</italic> with respect to allele
                                    <italic>a</italic></td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>p<sub>a</sub></italic>
                                    </td>
                                    <td align="left" colspan="2" rowspan="1">Probability of MHC allele
                                        <italic>a</italic> occurring in the target population</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="3" rowspan="1">
                                        <bold>Variables</bold>
                                    </td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">w<sub>a,i</sub> = 1</td>
                                    <td align="left" colspan="2" rowspan="1">If allele <italic>a</italic> is
                                        covered by an epitope from the <italic>i</italic>-th
                                        antigen, otherwise
                                        w<sub>a,i</sub> = 0</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">x<sub>e</sub> = 1</td>
                                    <td align="left" colspan="2" rowspan="1">If epitope <italic>e</italic>
                                        belongs to the optimal set, otherwise
                                        x<sub>e</sub> = 0</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">y<sub>a</sub> = 1</td>
                                    <td align="left" colspan="2" rowspan="1">If allele <italic>a</italic> is
                                        covered by the optimal set, otherwise
                                        y<sub>a</sub> = 0</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">z<sub>i</sub> = 1</td>
                                    <td align="left" colspan="2" rowspan="1">If an epitope from the
                                        <italic>i</italic>-th antigen belongs to the optimal set,
                                        otherwise
                                    z<sub>i</sub> = 0</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="3" rowspan="1">
                                        <bold>Integer Linear Program</bold>
                                    </td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1"/>
                                    <td align="left" colspan="1" rowspan="1">
                                        <italic>Maximize</italic>
                                    </td>
                                    <td align="left" colspan="1" rowspan="1">Maximize …</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1"/>
                                    <td align="left" colspan="1" rowspan="1">0.1·∑<italic>
                                            <sub>e</sub>
                                        </italic><sub>∈<italic>E</italic></sub>x<sub>e</sub>∑<italic>
                                            <sub>a</sub>
                                        </italic><sub>∈<italic>A</italic></sub><italic>p<sub>a</sub>
                                                i<sub>e</sub></italic><sub>,<italic>a</italic></sub>
                                        +</td>
                                    <td align="left" colspan="1" rowspan="1">… Overall immunogenicity and
                                        …</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1"/>
                                    <td align="left" colspan="1" rowspan="1">
                                        <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e013" xlink:type="simple"/></inline-formula>
                                    </td>
                                    <td align="left" colspan="1" rowspan="1">… Extend coverage of antigens, MHC
                                        alleles, …</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1"/>
                                    <td align="left" colspan="1" rowspan="1">
                                        <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e014" xlink:type="simple"/></inline-formula>
                                    </td>
                                    <td align="left" colspan="1" rowspan="1">… And MHC/antigen combinations.</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1"/>
                                    <td align="left" colspan="2" rowspan="1">
                                        <italic>Subject to</italic>
                                    </td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1"/>
                                    <td align="left" colspan="2" rowspan="1">All constraints from the extended
                                        ILP (<xref ref-type="table" rid="pcbi-1000246-t002">Table
                                        2</xref>)</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">∀<italic>i</italic>∈{1,…,<italic>n</italic>}</td>
                                    <td align="left" colspan="1" rowspan="1">
                                        <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e015" xlink:type="simple"/></inline-formula>
                                    </td>
                                    <td align="left" colspan="1" rowspan="1">Ensures that
                                        z<sub>i</sub> = 1 only if
                                        the <italic>i</italic>-th antigen is covered.</td>
                                </tr>
                                <tr>
                                    <td align="left" colspan="1" rowspan="1">∀<italic>i</italic>∈{1,…,<italic>n</italic>}
                                            <italic>a</italic>∈<italic>A</italic></td>
                                    <td align="left" colspan="1" rowspan="1">
                                        <inline-formula><inline-graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pcbi.1000246.e016" xlink:type="simple"/></inline-formula>
                                    </td>
                                    <td align="left" colspan="1" rowspan="1">Ensures that
                                        w<sub>a,i</sub> = 1 only if
                                        allele <italic>a</italic> is covered by an epitope from the
                                            <italic>i</italic>-th antigen.</td>
                                </tr>
                            </tbody>
                        </table></alternatives></table-wrap>
                </sec>
            </sec>
            <sec id="s2f">
                <title>Implementation</title>
                <p>We used ILOG CPLEX 9.1 <xref ref-type="bibr" rid="pcbi.1000246-ILOG1">[34]</xref> with its C++ interface ILOG
                    Concert Technology 2.1 to formulate and solve the ILP. It is, however, possible
                    to solve the ILPs with most other ILP solvers, e.g., MOSEK <xref ref-type="bibr" rid="pcbi.1000246-MOSEK1">[35]</xref> or freely available
                    packages like SCIP <xref ref-type="bibr" rid="pcbi.1000246-Achterberg1">[36]</xref>,<xref ref-type="bibr" rid="pcbi.1000246-Achterberg2">[37]</xref>.</p>
                <p>A formulation of the extended ILP (<xref ref-type="table" rid="pcbi-1000246-t002">Table 2</xref>) as ILOG CPLEX input, the required data for the comparison
                    with Vider-Shalit <italic>et al.</italic>
                    <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref> as well as the corresponding ILOG CPLEX output
                    can be found in the supplementary material (<xref ref-type="supplementary-material" rid="pcbi.1000246.s001">Texts S1</xref>,
                        <xref ref-type="supplementary-material" rid="pcbi.1000246.s002">S2</xref>,
                        <xref ref-type="supplementary-material" rid="pcbi.1000246.s003">S3</xref>).</p>
            </sec>
        </sec>
        <sec id="s3">
            <title>Results</title>
            <sec id="s3a">
                <title>Immunogenicity</title>
                <p>In order to show the effectiveness of the above-mentioned approach, we compare
                    our strategy with other published approaches and determine the theoretical gain
                    in immunogenicity or the number of epitopes required to achieve a similar
                    immunogenicity. While an experimental validation of this approach would be
                    valuable, it is beyond the scope of this paper, which focuses on the theoretical
                    foundations of the epitope selection. We compare our optimal strategy (best
                    overall immunogenicity, BOI) with two simple approaches:</p>
                <list list-type="bullet">
                    <list-item>
                        <p>randomly select <italic>k</italic> peptides out of a pool of good
                            epitopes (random set of epitopes, RSE) and</p>
                    </list-item>
                    <list-item>
                        <p>a simple greedy approach: pick the <italic>k</italic> best epitopes from
                            the set (best epitope-wise immunogenicity, BEI).</p>
                    </list-item>
                </list>
                <p>These three epitope selection strategies were used to select different-sized sets
                    of epitopes from a set of 4461 conserved (≥90%) HCV 9mers. For
                    BOI the basic ILP (<xref ref-type="table" rid="pcbi-1000246-t001">Table
                    1</xref>) was used to maximize overall immunogenicity. BEI selects the epitopes
                    with the highest sum of immunogenicities irrespective of the probabilities of
                    the corresponding MHC alleles. The overall immunogenicity of each epitope set
                    was determined and is displayed in <xref ref-type="fig" rid="pcbi-1000246-g002">Figure 2</xref>. For RSE, mean and standard deviation of 100 random
                    selections of different-sized epitope sets from the 100 most immunogenic
                    peptides are shown. The BEI curve shows sudden increases in overall
                    immunogenicity from 0 to 1, 10 to 13, and from 20 to 21 epitopes. This is caused
                    by the selection of epitopes which are highly immunogenic with respect to
                    HLA-A*0201, which is the most common
                    (<italic>p<sup>L</sup></italic> = 0.145) among
                    the considered alleles. All other selected epitopes are highly immunogenic with
                    respect to less common alleles like HLA-B*2705
                    (<italic>p<sup>L</sup></italic> = 0.015) or
                    HLA-B*5102
                    (<italic>p<sup>L</sup></italic> = 0.003). Thus
                    the former contribute more extensively to the overall immunogenicity than the
                    latter.</p>
                <fig id="pcbi-1000246-g002" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.g002</object-id>
                    <label>Figure 2</label>
                    <caption>
                        <title>Comparison of different epitope selection strategies with respect to
                            overall immunogenicity.</title>
                        <p>(A) Overall immunogenicity of different-sized epitope sets. (B) Overall
                            immunogenicity of a set of 10 epitopes. (C) Number of epitopes required
                            to achieve an overall immunogenicity of at least 2,699.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.g002" xlink:type="simple"/>
                </fig>
                <p>The average overall immunogenicity of the randomly chosen epitope sets is rather
                    low: scores range from about 308 for five epitopes, to 1,763 for 25 epitopes, to
                    2,699 for 40 epitopes. The other two approaches start from a minimum overall
                    immunogenicity of more than 900 and reach immunogenicities of 4,502 (BEI) and
                    6,142 (BOI), respectively. To achieve an immunogenicity of at least 2,699, BOI
                    requires five and BEI 12 epitopes (<xref ref-type="fig" rid="pcbi-1000246-g002">Figure 2</xref>).</p>
                <p>For sets with more than one epitope, the scores yielded by the BOI strategy are
                    between about 20% (13 epitopes) and 120% (6 epitopes)
                    higher than those of the BEI strategy.</p>
            </sec>
            <sec id="s3b">
                <title>Comparison with Vider-Shalit <italic>et al.</italic> on HCV</title>
                <p>In order to compare our approach to the work of Vider-Shalit <italic>et al.</italic>
                    <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref> we applied the ILP given in <xref ref-type="table" rid="pcbi-1000246-t002">Table 2</xref> to the HCV data and
                    27 of the 29 alleles from <xref ref-type="bibr" rid="pcbi.1000246-ViderShalit1">[26]</xref>. The alleles HLA-B<sup>*</sup>0702
                    and HLA-B<sup>*</sup>3501 were omitted, since none of the candidate
                    peptides binds to them. Probably due to an error in sequence processing
                    (personal communication with Yoram Louzoun), a peptide (AALENLVTL) which does
                    not belong to any of the proteins under consideration was included in the 25
                    epitopes selected by Vider-Shalit <italic>et al.</italic> We exclude this
                    peptide and base our comparison on sets of 24 epitopes.</p>
                <p>For the 24 epitopes to be selected, we require a minimum conservation of
                    90%, an allele coverage of 27, and an antigen coverage of at least
                    one epitope per antigen. Furthermore, only epitopes with antigen processing
                    scores within the top 30% of all sufficiently conserved candidate
                    peptides were allowed to be selected. The following 24 epitopes (hereafter
                            <italic>E<sub>ILP</sub></italic>) were selected:</p>
                <table-wrap id="pcbi-1000246-t005" position="float"><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">SFSIFLLAL<sup>*</sup></td>
                                <td align="left" colspan="1" rowspan="1">GHRMAWDMM<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">VYEADDVIL</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">YLYDHLAPM</td>
                                <td align="left" colspan="1" rowspan="1">GLRDLAVAV<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">GPTPLLYRL<sup>+</sup></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">QYLAGLSTL<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">NFVSGIQYL</td>
                                <td align="left" colspan="1" rowspan="1">VLSDFKTWL<sup>*</sup></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">GLYLFNWAV</td>
                                <td align="left" colspan="1" rowspan="1">ALYDVVSTL<sup>*</sup></td>
                                <td align="left" colspan="1" rowspan="1">RRCRASGVL<sup>+</sup></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">CFTPSPVVV<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">FLLLADARV<sup>*</sup></td>
                                <td align="left" colspan="1" rowspan="1">GPADGMVSK<sup>+</sup></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">TWVLVGGVL<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">IELGGKPAL<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">LAGGVLAAV</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">ARPDYNPPL<sup>+</sup></td>
                                <td align="left" colspan="1" rowspan="1">KLLPRLPGV</td>
                                <td align="left" colspan="1" rowspan="1">RHTPVNSWL<sup>+</sup></td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">WPLLLLLLA</td>
                                <td align="left" colspan="1" rowspan="1">VTYSLTGLW</td>
                                <td align="left" colspan="1" rowspan="1">YFVIFFVAA</td>
                            </tr>
                        </tbody>
                    </table></table-wrap>
                <p>Four epitopes (marked with *) are known HCV epitopes and can be found in
                    the Immune Epitope Database (IEDB, release 2008_4_1_3_28) <xref ref-type="bibr" rid="pcbi.1000246-Peters2">[24]</xref>. Another 11
                    epitopes (marked with +) are contained in known longer epitopes. The
                    overall immunogenicity of the selected set is 2,549. It includes binders for all
                    27 alleles with all 40 antigens being represented and covers 22.7% of
                    all MHC/antigen combinations. The average number of epitopes per individual of
                    the population is 13.3. The corresponding values of the epitope set selected by
                    Vider-Shalit <italic>et al.</italic> (hereafter <italic>E<sub>VS</sub></italic>)
                    are listed in <xref ref-type="table" rid="pcbi-1000246-t004">Table 4</xref>.</p>
                <table-wrap id="pcbi-1000246-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.t004</object-id><label>Table 4</label><caption>
                        <title>Overview over properties of HCV epitope sets selected using different
                            strategies.</title>
                    </caption><!--===== Grouping alternate versions of objects =====--><alternatives><graphic id="pcbi-1000246-t004-4" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.t004" xlink:type="simple"/><table>
                        <colgroup span="1">
                            <col align="left" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                            <col align="center" span="1"/>
                        </colgroup>
                        <thead>
                            <tr>
                                <td align="left" colspan="1" rowspan="1"/>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>E<sub>ILP</sub></italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>E<sub>VS</sub></italic>
                                </td>
                                <td align="left" colspan="1" rowspan="1">
                                    <italic>E<sub>Comb</sub></italic>
                                </td>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Overall immunogenicity</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>2,549</bold>
                                </td>
                                <td align="left" colspan="1" rowspan="1">125</td>
                                <td align="left" colspan="1" rowspan="1">2,177</td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Allele coverage</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>100%</bold>
                                </td>
                                <td align="left" colspan="1" rowspan="1">96.3%</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>100%</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Antigen coverage</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>100%</bold>
                                </td>
                                <td align="left" colspan="1" rowspan="1">87.5%</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>100%</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">MHC/antigen coverage</td>
                                <td align="left" colspan="1" rowspan="1">22.7%</td>
                                <td align="left" colspan="1" rowspan="1">19.2%</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>30.5%</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Population coverage</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>96.0%</bold>
                                </td>
                                <td align="left" colspan="1" rowspan="1">95.6%</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>96.0%</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Avg. number of epitopes per individual</td>
                                <td align="left" colspan="1" rowspan="1">13.3</td>
                                <td align="left" colspan="1" rowspan="1">11.4</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>17.3</bold>
                                </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1">Number of epitopes in IEDB</td>
                                <td align="left" colspan="1" rowspan="1">
                                    <bold>4</bold>
                                </td>
                                <td align="left" colspan="1" rowspan="1">1</td>
                                <td align="left" colspan="1" rowspan="1">1</td>
                            </tr>
                        </tbody>
                    </table></alternatives><table-wrap-foot>
                        <fn id="nt101">
                            <label/>
                            <p>Number of epitopes per set: 24. <italic>E<sub>ILP</sub></italic>: set
                                selected by our ILP, <italic>E<sub>VS</sub></italic>: set selected
                                by Vider-Shalit <italic>et al.</italic> without peptide AALENLVTL,
                                        <italic>E<sub>Comb</sub></italic>: set selected by our ILP
                                extended by aspects of the scoring function of Vider-Shalit
                                    <italic>et al.</italic></p>
                        </fn>
                    </table-wrap-foot></table-wrap>
                <p>To improve the MHC/antigen coverage while still aiming at high overall
                    immunogenicity we included the central part of the scoring function of
                    Vider-Shalit <italic>et al.</italic> in the objective function of our ILP. The
                    optimal epitope set with respect to the modified objective function (hereafter
                            <italic>E<sub>Comb</sub></italic>) is only 15% less
                    immunogenic than the original epitope set <italic>E<sub>ILP</sub></italic> and
                    more than 17 times more immunogenic than <italic>E<sub>VS</sub></italic>. As for
                    MHC/antigen coverage, it outperforms both (<xref ref-type="table" rid="pcbi-1000246-t004">Table 4</xref>). <italic>E<sub>Comb</sub></italic>
                    includes one epitope which is already known and 14 epitopes which are contained
                    in longer epitopes listed in the IEDB. <xref ref-type="fig" rid="pcbi-1000246-g003">Figure 3</xref> shows that when using the combined
                    objective function, 18 epitopes suffice to cover all alleles and antigens and
                    furthermore to outperform <italic>E<sub>VS</sub></italic> in terms of
                    immunogenicity (371) and MHC/antigen coverage (22.8%).</p>
                <fig id="pcbi-1000246-g003" position="float">
                    <object-id pub-id-type="doi">10.1371/journal.pcbi.1000246.g003</object-id>
                    <label>Figure 3</label>
                    <caption>
                        <title>Comparison of properties of HCV epitope sets selected using different
                            strategies.</title>
                        <p>(A) Overall immunogenicity. (B) Coverage of MHC/antigen pairs.</p>
                    </caption>
                    <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.g003" xlink:type="simple"/>
                </fig>
            </sec>
        </sec>
        <sec id="s4">
            <title>Discussion</title>
            <p>The selection of an epitope set with very high overall immunogenicity is crucial for
                the efficacy of an EV. Depending on the number of candidate epitopes to choose from,
                the number of alleles to be considered, as well as on the additional requirements,
                this problem can become very complex. In this work we propose a mathematical
                framework that can be used to solve this problem quickly for practical problem
                sizes. For several characteristic examples, we show that immunological requirements
                can be conveniently formulated as an ILP. The solution of this ILP yields an optimal
                set of epitopes: the set of epitopes that displays the highest overall
                immunogenicity of all sets which meet the pre-defined requirements. To our
                knowledge, this is the only approach that yields provably optimal solutions to the
                vaccine design problem for EVs. In contrast to previous heuristics, the optimal
                solution yields either significantly better overall immunogenicity for the same
                number of epitopes or a smaller number of required epitopes to reach the same level
                of immunogenicity. The flexibility of the framework allows selecting other objective
                functions, too, for example, maximizing antigen or allele coverage.</p>
            <p>The optimal selection of epitopes yields—in theory—significantly
                higher overall immunogenicities than other strategies (e.g., selection of the best
                epitopes or evolutionary algorithms). However, one should keep in mind that the
                selection of the epitopes is still a difficult and controversial issue since the
                underlying processes are not yet fully understood. In particular, the interplay of
                different epitopes poses a difficult problem. Competition between epitopes will
                probably result in reduced immunogenicity of peptide cocktails, an effect that has
                been observed in various studies.</p>
            <p>On the one hand, this represents a problem, because the assumption of independence
                between epitopes is one of the key assumptions made in this work (and in all related
                approaches). Lacking an accurate model of these competition effects, however, it
                seems like the best assumption one can make. On the other hand, the effects of
                competition are a compelling reason to employ this type of selection approach.
                Competition effects will be less severe for fewer peptides, therefore a selection
                procedure that yields the same overall immunogenicity with fewer peptides can in
                fact mitigate this problem. Assuming that competition primarily arises between
                epitopes binding to the same MHC allele, one can also introduce additional
                constraints to reduce competition (e.g., find the best combination that contains at
                most two epitopes per allele). In the long run, a thorough quantitative analysis of
                larger vaccination studies might shed some light on these effects and their
                importance.</p>
            <p>Also, the notion of immunogenicity alone, or the ability to evoke an immune response
                in a certain fraction of patients, is not necessarily a true measure of quality for
                a vaccine. In their recent review on the quality of the T-cell response <xref ref-type="bibr" rid="pcbi.1000246-Seder1">[38]</xref>, Seder
                    <italic>et al.</italic> argue that protective T-cell responses are too complex
                to be sufficiently described by a measure of magnitude alone. An adequate metric
                would thus not only account for the magnitude but also for the multifunctional
                quality of the response. The flexibility of our framework allows for the
                incorporation of a different quality measure for immunogenicity and a careful
                comparison of the peptide cocktails suggested by different objective functions would
                be very interesting.</p>
            <p>In their review of EVs, Purcell <italic>et al.</italic>
                <xref ref-type="bibr" rid="pcbi.1000246-Purcell1">[5]</xref> point
                out that, to date, there are no human EVs on the market. This is mainly attributed
                to the difficulties associated with peptide stability and delivery. Various delivery
                strategies <xref ref-type="bibr" rid="pcbi.1000246-Sette1">[39]</xref> are being explored in clinical studies. In an
                extension of this work, one might therefore also include considerations related to
                the peptide delivery. For <italic>beads-on-a-string</italic> type vaccines, the
                selected epitopes are combined into one larger polypeptide. As the specificities of
                the antigen processing pathway have to be taken into account when constructing the
                polypeptide, the order of the epitopes as well as possible spacer sequences need to
                be optimized (e.g. through incorporation of a proteasomal cleavage matrix).</p>
        </sec>
        <sec id="s5">
            <title>Supporting Information</title>
            <supplementary-material id="pcbi.1000246.s001" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.s001" xlink:type="simple">
                <label>Text S1</label>
                <caption>
                    <p>ILOG CPLEX input. AMPL formulation of the extended ILP given in <xref ref-type="table" rid="pcbi-1000246-t002">Table 2</xref> adapted for the
                        comparison with Vider-Shalit et al.</p>
                    <p>(3.00 KB TXT)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pcbi.1000246.s002" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.s002" xlink:type="simple">
                <label>Text S2</label>
                <caption>
                    <p>HCV data (in AMPL format) used for the comparison with Vider-Shalit et al.
                        Only highly conserved peptides
                        (&gt; = 90%) were considered
                        when generating this file.</p>
                    <p>(1.70 MB TXT)</p>
                </caption>
            </supplementary-material>
            <supplementary-material id="pcbi.1000246.s003" mimetype="text/plain" position="float" xlink:href="info:doi/10.1371/journal.pcbi.1000246.s003" xlink:type="simple">
                <label>Text S3</label>
                <caption>
                    <p>ILOG CPLEX output.</p>
                    <p>(2.00 KB TXT)</p>
                </caption>
            </supplementary-material>
        </sec>
    </body>
    <back>
        <ack>
            <p>We thank Andreas Kämper and Magdalena Feldhahn for comments on the
                manuscript.</p>
        </ack>
        <ref-list>
            <title>References</title>
            <ref id="pcbi.1000246-Moutschen1">
                <label>1</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Moutschen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Léonard</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sokal</surname>
                            <given-names>EM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Smets</surname>
                            <given-names>F</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Haumont</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Phase I/II studies to evaluate safety and immunogenicity of a
                        recombinant gp350 Epstein-Barr virus vaccine in healthy adults.</article-title>
                    <source>Vaccine</source>
                    <volume>25</volume>
                    <fpage>4697</fpage>
                    <lpage>4705</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Goepfert1">
                <label>2</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Goepfert</surname>
                            <given-names>PA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tomaras</surname>
                            <given-names>GD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Horton</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Montefiori</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ferrari</surname>
                            <given-names>G</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Durable HIV-1 antibody and T-cell responses elicited by an
                        adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.</article-title>
                    <source>Vaccine</source>
                    <volume>25</volume>
                    <fpage>510</fpage>
                    <lpage>518</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Nemunaitis1">
                <label>3</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nemunaitis</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Meyers</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Senzer</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Cunningham</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>West</surname>
                            <given-names>H</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>Phase I Trial of sequential administration of recombinant DNA and
                        adenovirus expressing L523S protein in early stage nonsmall-cell lung
                        cancer.</article-title>
                    <source>Mol Ther</source>
                    <volume>13</volume>
                    <fpage>1185</fpage>
                    <lpage>1191</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-ManciniBourgine1">
                <label>4</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Mancini-Bourgine</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fontaine</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bréchot</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pol</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Michel</surname>
                            <given-names>ML</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>Immunogenicity of a hepatitis B DNA vaccine administered to
                        chronic HBV carriers.</article-title>
                    <source>Vaccine</source>
                    <volume>24</volume>
                    <fpage>4482</fpage>
                    <lpage>4489</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Purcell1">
                <label>5</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Purcell</surname>
                            <given-names>AW</given-names>
                        </name>
                        <name name-style="western">
                            <surname>McCluskey</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rossjohn</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>More than one reason to rethink the use of peptides in vaccine
                        design.</article-title>
                    <source>Nat Rev Drug Discov</source>
                    <volume>6</volume>
                    <fpage>404</fpage>
                    <lpage>414</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Depil1">
                <label>6</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Depil</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Moralès</surname>
                            <given-names>O</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Castelli</surname>
                            <given-names>FA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Delhem</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>François</surname>
                            <given-names>V</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Determination of a HLA II promiscuous peptide cocktail as
                        potential vaccine against EBV latency II malignancies.</article-title>
                    <source>J Immunother</source>
                    <volume>30</volume>
                    <fpage>215</fpage>
                    <lpage>226</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-ChianeseBullock1">
                <label>7</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Chianese-Bullock</surname>
                            <given-names>KA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Irvin</surname>
                            <given-names>WP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Petroni</surname>
                            <given-names>GR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Murphy</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Smolkin</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>A multipeptide vaccine is safe and elicits T-cell responses in
                        participants with advanced stage ovarian cancer.</article-title>
                    <source>J Immunother</source>
                    <volume>31</volume>
                    <fpage>420</fpage>
                    <lpage>430</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Kenter1">
                <label>8</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kenter</surname>
                            <given-names>GG</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Welters</surname>
                            <given-names>MJP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Valentijn</surname>
                            <given-names>ARPM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lowik</surname>
                            <given-names>MJG</given-names>
                        </name>
                        <name name-style="western">
                            <surname>van der Meer</surname>
                            <given-names>DMAB</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2008</year>
                    <article-title>Phase I immunotherapeutic trial with long peptides spanning the
                        E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage
                        cervical cancer patients shows low toxicity and robust immunogenicity.</article-title>
                    <source>Clin Cancer Res</source>
                    <volume>14</volume>
                    <fpage>169</fpage>
                    <lpage>177</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Yajima1">
                <label>9</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Yajima</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yamanaka</surname>
                            <given-names>R</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Mine</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tsuchiya</surname>
                            <given-names>N</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Homma</surname>
                            <given-names>J</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Immunologic evaluation of personalized peptide vaccination for
                        patients with advanced malignant glioma.</article-title>
                    <source>Clin Cancer Res</source>
                    <volume>11</volume>
                    <fpage>5900</fpage>
                    <lpage>5911</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Slingluff1">
                <label>10</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Slingluff</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Petroni</surname>
                            <given-names>GR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yamshchikov</surname>
                            <given-names>GV</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Barnd</surname>
                            <given-names>DL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Eastham</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>Clinical and immunologic results of a randomized phase II trial
                        of vaccination using four melanoma peptides either administered in
                        granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on
                        dendritic cells.</article-title>
                    <source>J Clin Oncol</source>
                    <volume>21</volume>
                    <fpage>4016</fpage>
                    <lpage>4026</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Slingluff2">
                <label>11</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Slingluff</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Petroni</surname>
                            <given-names>GR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chianese-Bullock</surname>
                            <given-names>KA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Smolkin</surname>
                            <given-names>ME</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hibbitts</surname>
                            <given-names>S</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Immunologic and clinical outcomes of a randomized phase II trial
                        of two multipeptide vaccines for melanoma in the adjuvant setting.</article-title>
                    <source>Clin Cancer Res</source>
                    <volume>13</volume>
                    <fpage>6386</fpage>
                    <lpage>6395</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-SinghJasuja1">
                <label>12</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Singh-Jasuja</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Emmerich</surname>
                            <given-names>NPN</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rammensee</surname>
                            <given-names>HG</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>The Tübingen approach: identification, selection, and
                        validation of tumor-associated HLA peptides for cancer therapy.</article-title>
                    <source>Cancer Immunol Immunother</source>
                    <volume>53</volume>
                    <fpage>187</fpage>
                    <lpage>195</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Rammensee1">
                <label>13</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Rammensee</surname>
                            <given-names>H</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bachmann</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Emmerich</surname>
                            <given-names>NP</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bachor</surname>
                            <given-names>OA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Stevanovic</surname>
                            <given-names>S</given-names>
                        </name>
                    </person-group>
                    <year>1999</year>
                    <article-title>SYFPEITHI: database for MHC ligands and peptide motifs.</article-title>
                    <source>Immunogenetics</source>
                    <volume>50</volume>
                    <fpage>213</fpage>
                    <lpage>219</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Parker1">
                <label>14</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Parker</surname>
                            <given-names>KC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bednarek</surname>
                            <given-names>MA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Coligan</surname>
                            <given-names>JE</given-names>
                        </name>
                    </person-group>
                    <year>1994</year>
                    <article-title>Scheme for ranking potential HLA-A2 binding peptides based on
                        independent binding of individual peptide side-chains.</article-title>
                    <source>J Immunol</source>
                    <volume>152</volume>
                    <fpage>163</fpage>
                    <lpage>175</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Dnnes1">
                <label>15</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Dönnes</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kohlbacher</surname>
                            <given-names>O</given-names>
                        </name>
                    </person-group>
                    <year>2006</year>
                    <article-title>SVMHC: a server for prediction of MHC-binding peptides.</article-title>
                    <source>Nucleic Acids Res</source>
                    <volume>34</volume>
                    <fpage>W194</fpage>
                    <lpage>W197</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Buus1">
                <label>16</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Buus</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lauemøller</surname>
                            <given-names>SL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Worning</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kesmir</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Frimurer</surname>
                            <given-names>T</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>Sensitive quantitative predictions of peptide-MHC binding by a
                        ‘Query by Committee’ artificial neural network approach.</article-title>
                    <source>Tissue Antigens</source>
                    <volume>62</volume>
                    <fpage>378</fpage>
                    <lpage>384</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Nielsen1">
                <label>17</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nielsen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lundegaard</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Worning</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lauemøller</surname>
                            <given-names>SL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lamberth</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2003</year>
                    <article-title>Reliable prediction of T-cell epitopes using neural networks with
                        novel sequence representations.</article-title>
                    <source>Protein Sci</source>
                    <volume>12</volume>
                    <fpage>1007</fpage>
                    <lpage>1017</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Nielsen2">
                <label>18</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nielsen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lundegaard</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Worning</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Hvid</surname>
                            <given-names>CS</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lamberth</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2004</year>
                    <article-title>Improved prediction of MHC class I and class II epitopes using a
                        novel gibbs sampling approach.</article-title>
                    <source>Bioinformatics</source>
                    <volume>20</volume>
                    <fpage>1388</fpage>
                    <lpage>1397</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Schafer1">
                <label>19</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Schafer</surname>
                            <given-names>JR</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jesdale</surname>
                            <given-names>BM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>George</surname>
                            <given-names>JA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kouttab</surname>
                            <given-names>NM</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Groot</surname>
                            <given-names>ASD</given-names>
                        </name>
                    </person-group>
                    <year>1998</year>
                    <article-title>Prediction of well-conserved HIV-1 ligands using a matrix-based
                        algorithm, EpiMatrix.</article-title>
                    <source>Vaccine</source>
                    <volume>16</volume>
                    <fpage>1880</fpage>
                    <lpage>1884</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Bui1">
                <label>20</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Bui</surname>
                            <given-names>HH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sidney</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Peters</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sathiamurthy</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sinichi</surname>
                            <given-names>A</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>Automated generation and evaluation of specific mhc binding
                        predictive tools: Arb matrix applications.</article-title>
                    <source>Immunogenetics</source>
                    <volume>57</volume>
                    <fpage>304</fpage>
                    <lpage>314</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Peters1">
                <label>21</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Peters</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Sette</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Generating quantitative models describing the sequence
                        specificity of biological processes with the stabilized matrix method.</article-title>
                    <source>BMC Bioinformatics</source>
                    <volume>6</volume>
                    <fpage>132</fpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Nielsen3">
                <label>22</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nielsen</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lundegaard</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lund</surname>
                            <given-names>O</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Prediction of MHC class II binding affinity using SMM-align, a
                        novel stabilization matrix alignment method.</article-title>
                    <source>BMC Bioinformatics</source>
                    <volume>8</volume>
                    <fpage>238</fpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Sturniolo1">
                <label>23</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sturniolo</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bono</surname>
                            <given-names>E</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Ding</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Raddrizzani</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Tuereci</surname>
                            <given-names>O</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>1999</year>
                    <article-title>Generation of tissue-specific and promiscuous HLA ligand
                        databases using DNA microarrays and virtual HLA class II matrices.</article-title>
                    <source>Nat Biotechnol</source>
                    <volume>17</volume>
                    <fpage>555</fpage>
                    <lpage>561</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Peters2">
                <label>24</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Peters</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bui</surname>
                            <given-names>HH</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Frankild</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Nielson</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Lundegaard</surname>
                            <given-names>C</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2006</year>
                    <article-title>A community resource benchmarking predictions of peptide binding
                        to MHC-I molecules.</article-title>
                    <source>PLoS Comput Biol</source>
                    <volume>2</volume>
                    <fpage>e65</fpage>
                    <comment>doi:10.1371/journal.pcbi.0020065</comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Groot1">
                <label>25</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Groot</surname>
                            <given-names>ASD</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Marcon</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bishop</surname>
                            <given-names>EA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rivera</surname>
                            <given-names>D</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kutzler</surname>
                            <given-names>M</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2005</year>
                    <article-title>HIV vaccine development by computer assisted design: the GAIA
                        vaccine.</article-title>
                    <source>Vaccine</source>
                    <volume>23</volume>
                    <fpage>2136</fpage>
                    <lpage>2148</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-ViderShalit1">
                <label>26</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Vider-Shalit</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Raffaeli</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Louzoun</surname>
                            <given-names>Y</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Virus-epitope vaccine design: informatic matching the HLA-I
                        polymorphism to the virus genome.</article-title>
                    <source>Mol Immunol</source>
                    <volume>44</volume>
                    <fpage>1253</fpage>
                    <lpage>1261</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Fischer1">
                <label>27</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Fischer</surname>
                            <given-names>W</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Perkins</surname>
                            <given-names>S</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Theiler</surname>
                            <given-names>J</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Bhattacharya</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yusim</surname>
                            <given-names>K</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Polyvalent vaccines for optimal coverage of potential T-cell
                        epitopes in global HIV-1 variants.</article-title>
                    <source>Nat Med</source>
                    <volume>13</volume>
                    <fpage>100</fpage>
                    <lpage>106</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Nickle1">
                <label>28</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Nickle</surname>
                            <given-names>DC</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Rolland</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Jensen</surname>
                            <given-names>MA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pond</surname>
                            <given-names>SLK</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Deng</surname>
                            <given-names>W</given-names>
                        </name>
                        <etal/>
                    </person-group>
                    <year>2007</year>
                    <article-title>Coping with viral diversity in HIV vaccine design.</article-title>
                    <source>PLoS Comput Biol</source>
                    <volume>3</volume>
                    <fpage>e75</fpage>
                    <comment>doi:10.1371/journal.pcbi.0030075</comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Schrijver1">
                <label>29</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Schrijver</surname>
                            <given-names>A</given-names>
                        </name>
                    </person-group>
                    <year>1986</year>
                    <source>Theory of linear and integer programming</source>
                    <publisher-loc>New York</publisher-loc>
                    <publisher-name>John Wiley &amp; Sons</publisher-name>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Kingsford1">
                <label>30</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kingsford</surname>
                            <given-names>CL</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Chazelle</surname>
                            <given-names>B</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Solving and analyzing side-chain positioning problems using
                        linear and integer programming.</article-title>
                    <source>Bioinformatics</source>
                    <volume>21</volume>
                    <fpage>1028</fpage>
                    <lpage>1036</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Kuiken1">
                <label>31</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Kuiken</surname>
                            <given-names>C</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Yusim</surname>
                            <given-names>K</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Boykin</surname>
                            <given-names>L</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Richardson</surname>
                            <given-names>R</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>The Los Alamos hepatitis C sequence database.</article-title>
                    <source>Bioinformatics</source>
                    <volume>21</volume>
                    <fpage>379</fpage>
                    <lpage>384</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Edgar1">
                <label>32</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Edgar</surname>
                            <given-names>RC</given-names>
                        </name>
                    </person-group>
                    <year>2004</year>
                    <article-title>MUSCLE: multiple sequence alignment with high accuracy and high
                        throughput.</article-title>
                    <source>Nucleic Acids Res</source>
                    <volume>32</volume>
                    <fpage>1792</fpage>
                    <lpage>1797</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Dnnes2">
                <label>33</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Dönnes</surname>
                            <given-names>P</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Kohlbacher</surname>
                            <given-names>O</given-names>
                        </name>
                    </person-group>
                    <year>2005</year>
                    <article-title>Integrated modeling of the major events in the MHC class I
                        antigen processing pathway.</article-title>
                    <source>Protein Sci</source>
                    <volume>14</volume>
                    <fpage>2132</fpage>
                    <lpage>2140</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-ILOG1">
                <label>34</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">ILOG, Inc</collab>
                    <year>2005</year>
                    <article-title>ILOG CPLEX, version 9.1.</article-title>
                    <comment>
                        <ext-link ext-link-type="uri" xlink:href="http://www.ilog.com" xlink:type="simple">http://www.ilog.com</ext-link>
                    </comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-MOSEK1">
                <label>35</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <collab xlink:type="simple">MOSEK ApS</collab>
                    <article-title>Mosek.</article-title>
                    <comment>
                        <ext-link ext-link-type="uri" xlink:href="http://www.mosek.com" xlink:type="simple">http://www.mosek.com</ext-link>
                    </comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Achterberg1">
                <label>36</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Achterberg</surname>
                            <given-names>T</given-names>
                        </name>
                    </person-group>
                    <year>2007</year>
                    <article-title>Constraint Integer Programming.</article-title>
                    <comment>Ph.D. thesis, Technische Universität Berlin</comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Achterberg2">
                <label>37</label>
                <element-citation publication-type="other" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Achterberg</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Berthold</surname>
                            <given-names>T</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Pfetsch</surname>
                            <given-names>M</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Wolter</surname>
                            <given-names>K</given-names>
                        </name>
                    </person-group>
                    <article-title>SCIP (Solving Constraint Integer Programs).</article-title>
                    <comment>
                        <ext-link ext-link-type="uri" xlink:href="http://scip.zib.de" xlink:type="simple">http://scip.zib.de</ext-link>
                    </comment>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Seder1">
                <label>38</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Seder</surname>
                            <given-names>RA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Darrah</surname>
                            <given-names>PA</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Roederer</surname>
                            <given-names>M</given-names>
                        </name>
                    </person-group>
                    <year>2008</year>
                    <article-title>T-cell quality in memory and protection: implications for vaccine
                        design.</article-title>
                    <source>Nat Rev Immunol</source>
                    <volume>8</volume>
                    <fpage>247</fpage>
                    <lpage>258</lpage>
                </element-citation>
            </ref>
            <ref id="pcbi.1000246-Sette1">
                <label>39</label>
                <element-citation publication-type="journal" xlink:type="simple">
                    <person-group person-group-type="author">
                        <name name-style="western">
                            <surname>Sette</surname>
                            <given-names>A</given-names>
                        </name>
                        <name name-style="western">
                            <surname>Fikes</surname>
                            <given-names>J</given-names>
                        </name>
                    </person-group>
                    <year>2003</year>
                    <article-title>Epitope-based vaccines: an update on epitope identification,
                        vaccine design and delivery.</article-title>
                    <source>Curr Opin Immunol</source>
                    <volume>15</volume>
                    <fpage>461</fpage>
                    <lpage>470</lpage>
                </element-citation>
            </ref>
        </ref-list>
        
    </back>
</article>